Maurice Perol
@MP_3855
ID:1235040944
02-03-2013 15:32:48
779 Tweets
628 Followers
195 Following
C’est maintenant l’heure de la « lecture critique d’articles » : merci à Florian Guisier et Aurélie Swalduz! #17eme_Réunion_Clinico_Pathologique_en_Oncologie_Thoracique GFPC
Fantastic presentation by Zosia Piotrowska - balanced, thoughtful and poised discussion of MARIPOSA and MARIPOSA-2 ESMO Open #ESMO23
➡️ Highlights that chronic toxicities, even low grade can affect QOL, cc Jill Feldman
➡️ Patient oriented approach will be KEY!
EGFR Resisters
We publish an update on the multidisciplinary management of TKI-induced diarrhea, a problem that affects the patient's quality of life, even in grade 1 due to long-term treatment Instituto Nacional de Cancerología UFOT INCan Jenny Turcott Andres F. Cardona
journals.sagepub.com/doi/epub/10.11…
Michael Duruisseaux And access to selpercatinib for the French RET+ NSCLC patients for whom there is no drug available in early access. @HAS refused this access in absence of CT comparative trials by contrast to other UE countries. It is time to urgently change this inequality Ministère de la Santé et de la Prévention
Pilar Garrido Lizza Hendriks d.planchard Anne-Marie Dingemans Enriqueta Felip ESMO - Eur. Oncology Beaumont RCSI Cancer Centre - charocampelo: neoadj + adj IO
- me! Jarushka Naidoo: mesothelioma, thymoma
Lisbon in November, will be fun
ESMO - Eur. Oncology #LCSM #IrishLungCancerAlliance #IrishLungCancerCommunity RCSI Research and Innovation
Stephen V Liu, MD It is a very important news for French pts with RET fusion advanced NSCLC as France did not accept selpercatib nor praseltinib access even conditional Haute Autorité de santé Ministère de la Santé et de la Prévention Aurélien Rousseau it is time to have to selpercatinib access. alk ros1 france cancer poumon Mon Réseau Cancer du Poumon IFCT lung
The ESMO Handbook on Nutrition and Cancer (Second edition) is out now.
Excellent publication and
free for ESMO - Eur. Oncology
Members. Please download
oncologypro.esmo.org/education-libr…
OncoAlert BTOG Christie Library
Vivek Subbiah, MD denis Moro-Sibilot Haute Autorité de santé cela pourrait il être suffisant pour débloquer la situation en France? Mon Réseau Cancer du Poumon alk ros1 france cancer poumon Julien Mazieres Benjamin Besse Maurice Perol Marie Wislez Michael Duruisseaux IFCT lung Laurent Greillier
d.planchard Gustave Roussy Centre International des Cancers Thoraciques En effet, dans beaucoup d’établissements AP-HP Hôpital Tenon AP-HP. Mais nous savons aussi que les contraintes des essais font que 5, 10, 30% des malades seront incluables; c’est l’objet pour les autres des accès précoces pour des molécules d’intérêts Julien Mazieres Maurice Perol denis Moro-Sibilot
#ASCO23 ASCO
Fantastic discussion of LIBELULE - a study of early integration of Liq Bx in #NSCLC Joel W. Neal, MD, PhD
- reduced Time to Tx start
- ctDNA tumor fraction may be helpful
OncoAlert LungCancerRx 🫁💊